The findings from genome-wide association studies hold enormous potential for novel insight into disease mechanisms. Unfortunately, progress in mapping low-risk association signals to the underlying functional sequence variants (FSVs) involved in disease has been challenging. Simple sequence study designs are insufficient, as the vast numbers of statistically comparable variants and a limited knowledge of non-coding regulatory elements complicate prioritization. Furthermore, large sample sizes are typically required for adequate power to identify the initial association signals. One important question is whether similar sample sizes need to be sequenced to identify the FSVs. Here, we present a proof of principle example of an extreme discordant design to map FSVs at the 2q33 lowrisk breast cancer locus. Our approach employed DNA sequencing of a small number of discordant haplotypes to efficiently identify candidate-FSVs. Our results were consistent with those from a 2000-fold larger, traditional imputation-based fine-mapping study. To prioritize further, we used expression-quantitative trait locus analysis of RNA sequencing from breast tissues, gene regulation annotations from the ENCODE consortium, and functional assays for differential enhancer activities. Notably, we implicate three regulatory variants at 2q33 that target CASP8 (rs3769823, rs3769821 in CASP8, and rs10197246 in ALS2CR12) as functionally relevant. We conclude that nested discordant haplotype sequencing is a promising approach to aid mapping of low-risk association loci. The ability to include more sophisticated and efficient sequencing designs into mapping efforts presents an opportunity for the field to capitalize on the potential of association loci and accelerate translation of association signals to their underlying FSVs.
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Introduction
The large number of compelling disease loci identified from disease-association studies(e.g.1-4) provides immense potential for novel insight into disease mechanisms and new opportunities for diagnosis, prevention and treatment. To date, 2,511 genome-wide association studies [GWAS] of 1,353 traits have generated 8,345 hits at p≤5×10 -8 (5).
However, the task of identifying the underlying FSVs has proven extremely challenging and, thus far, very few FSV have been identified for these types of low-risk disease loci(e.g. [6] [7] [8] .
A number of factors contribute to the challenge, including cost and an inadequate functional knowledgebase. Performing DNA sequencing (DNAseq) of the disease loci would capture the FSVs, but this is often financially impractical for large case-control designs (GWAS for common traits can include 100,000s of cases and controls). Furthermore, empirical evidence suggests that the vast majority of FSVs for these loci will be common, non-coding variants influencing gene expression (9) . Hence, the identification of the FSV via simple prioritization of the sequence data may be difficult because many variants will be statistically comparable and our understanding of non-coding regulatory elements is incomplete.
Instead of complete DNAseq of a GWAS region, a standard approach to identify cFSVs is a more detailed statistical interrogation of the region ("fine-mapping"). Often these finemapping studies are undertaken in the same large sample sets as the initial analyses, they explore evidence for multiple signals and use statistical imputation to estimate the association evidence for other common and rare variants in the region that were not directly genotyped (10) . A caveat of statistical imputation is that it relies on external imputation panels that are not only distinct from the target populations, but are often much 
RAF=0.34 in cases). Even if the associated SNP is in perfect linkage disequilibrium (LD)
with the FSV (r 2 =1.0), greater than 85,000 samples are required to identify it with 80%
power at a significance of α=5×10 -8 . Now consider a haplotype discordant design: cases homozygous for the risk haplotype and controls with zero copies. If the risk haplotype were a perfect proxy, the FSV RAF would be enriched to 1.0 in cases and reduced to 0.0 in controls. While enrichment will not be perfect, it will be greatly enhanced; thus if RAFs become 0.9 (cases) and 0.1 (controls), a sample size of only 28 has 80% power at α=5×10 -8 (see Supplemental Methods for more details).
As proof-of-concept we present a discordant haplotype HTS DNAseq study in 38 individuals for the 2q33 (CASP8/ALS2CR12) region, a breast cancer risk locus (11) . In order to address the lack of knowledge surrounding gene regulation and better prioritize our sequence variants, we supplemented publicly available annotations with RNAseq in normal and tumor breast tissue, and identify three FSVs affecting enhancer activity.
Methods
An overview of study design detailing the sample sets used for the DNAseq and RNAseq analyses can be found in the Supplemental Figure. 
DNA sequencing and variant prioritization
Haplotype mining was performed previously using hapConstructor (12) SVs had an allele with AF≥0.9 in cases, but only 18 of these also had AF≤0.1 in controls. For these 18, the RAF varied from 0.905-1.0 in cases, and from 0.0-0.094 in controls. One variant aligned perfectly with expectations (rs3769821, RAFs of 1.0 and 0.0 in cases and controls, respectively). Chi-squared tests of allele counts by case/control group were calculated to help interpret these observed discrepant RAF frequencies. All were highly significant (6.9×10 -13 ≤p≤2.8×10 -18 , Table 1 ). Background frequencies for the risk alleles for the CEU/GBR 1000G samples are shown in Table 1 . per million mapped reads for CFLAR, CASP10, CASP8, respectively, and differential analyses were performed all 3 genes in both normal and tumor tissues. We note that the average standardized counts for CASP10 fell below 20 counts per million mapped reads, and more caution should be exercised in interpreting findings for that gene in these data.
RNA sequencing and differential expression

Comparison to traditional fine-mapping: Meta association evidence from BCAC and GWAS
The R package metaphor (http://cran.r-project.org/web/packages/metafor) was used to carry out a meta-analysis for the cFSVs, based on the odds ratios and 95% confidence intervals provided for 46,450 cases, 42,600 controls (BCAC) and 22,627 cases and 10,052 controls (9 GWAS) in Lin et al (11) .
Potential functional relevance: Luciferase assays for enhancer activity
Variants rs3769823, rs3769821 and rs10197246 were chosen to investigate for ability to affect enhancer activity. To create the enhancer constructs, we performed PCR using genomic DNA from T-47D, which is homozygous for risk alleles at all three SNPs, and MCF10A, which is homozygous for neutral alleles, using the following primer pairs: 
Ethics Approvals
The women whose samples were involved in the DNAseq and RNAseq experiments described here were enrolled in studies approved by the University of Utah Institutional (Figure 1 ).
In the optimal situation, the FSV would reside on all 42 case chromosomes and no control chromosomes. In selecting cFSVs, we allowed 10% discrepancy, such that a SV was considered a candidate if RAF≥0.9 in cases and RAF≤0.1 in controls. This resulted in 18 cFSVs (15 in CASP8 and 3 in the adjacent gene ALS2CR12): one was exonic (CASP8), 16 intronic, and one in the 3' UTR of ALS2CR12 ( Table 1) . As expected, allele frequency differences between the cases and controls were all highly significant due to the discordant design (all p<10 -12 ). Risk alleles were all very common in the general population (1000G RAFs=0.27-0.40).
To assess the cFSV for potential functional consequences, we performed eQTL analysis using high quality RNAseq data for CASP8, CASP10, and CFLAR in 86 normal tissue and 68 tumor samples, examining expression differences based on germ-line DNA genotype data for 16/18 cFSVs ( This small, but highly focused haplotype discordant study, demonstrates that cFSVs can be identified that are associated with gene expression. However, equally important is how this information aligns and adds value to results from a traditional "fine-mapping" study. To achieve this, we aligned our cFSVs with those suggested by the fine-mapping study by the Breast Cancer Association Consortium (BCAC) that used 89,050 samples and 1,733 imputation fine-mapping SNPs across the same 1 Mb region (11) . The BCAC study identified one region that achieved genome-wide significance (referred to as iCHAV1, p=1.1×10 -9 )(11). The BCAC iCHAV1 SNP set corresponds closely with the set of cFSVs identified here.
Nine SVs were present in both sets, seven present only in the BCAC set, and nine present only in the discordant haplotype set ( Table 3 ). The seven SVs present only in the BCAC results were in genomic regions 1000G has designated as inaccessible to HTS technologies and were not captured by our sequencing baits. This highlights a limitation of HTS technology, but also suggests caution with imputation in this region, which is based on low coverage sequence data (6 of the 7 missed SNPs were imputed). We genotyped the remaining SV, rs10197246, which indicated it would have passed our cFSV criteria (Table   3 ). Of the nine cFSVs present only in our discordant haplotype study, several only narrowly missed BCAC inclusion. For example, our set included both rs6735656 and rs10635401, but only the latter was captured in the BCAC set due to slight superiority in significance in that data. Interestingly, in a combined BCAC+9 GWAS meta-analysis, the order of significance is reversed for these two SNPs (Table 3) . Hence, the discordant haplotype DNAseq study not only aligned with, but also added value to the very large BCAC finemapping study.
Based on the combined 25 cFSVs, we used publicly available annotations and RNAseq eQTL results to prioritize for functional follow-up (Table 3 ). The three most compelling cFSVs are rs3769823, rs3769821, and rs10197246. All three yield highly significant results in both the discordant haplotype and traditional fine-mapping approaches and are associated with CASP8 expression differences in normal breast tissue. The first two reside 435 bp apart in a promoter proximal region that exhibits DNAse I hypersensitivity in mammary epithelial and breast cancer cell lines, and binds multiple transcription factors (STAT3, MYC, Pol2 and CTCF) based on ENCODE data (22) . Also notable are results from an eQTL study in blood(23), indicating highly significant decreased CASP8 expression associated with these cFSVs (Z=-5.44, p=5.3×10 -8 ), and suggesting the expression signature is also readily observed in blood ( Table 3) . The latter cFSV, rs10197246, resides in a potential distal regulatory element, 80 kb from a CASP8 promoter, that is bound by MYC in the breast cancer cell line MCF-7. Hence, MYC-triggered apoptosis may be one possible mechanism for the association, worthy of investigation.
We tested for functional differences between allelic variants of rs3769823, rs3769821 and rs10197246, by performing enhancer assays based on a luciferase reporter gene in cell lines derived from MCF10A (normal breast tissue) and T-47D (breast tumor). Figure 4 shows the enhancer activity of the risk and neutral alleles in each cell line. We found that the region containing the risk alleles of rs3769821 and rs3769823 drove significantly lower gene expression in both the normal and tumor cell lines compared to the same region harboring the neutral alleles. The region surrounding the risk allele of rs10197246 produced ~3-fold lower expression compared to the neutral allele in the normal breast cell line, but there was no difference between alleles in tumor cells. Overall, the functional results are consistent with our eQTL study, and suggest that these cFSV cause reproducible reduction of CASP8 expression in normal breast tissue.
Discussion
In our proof of principle analysis of the 2q33 locus for breast cancer, we considered our focused extreme discordant haplotype study together with the much larger BCAC traditional fine-mapping study, in addition to tissue-specific RNAseq and public annotations, to select rs3769823, rs3769821, and rs10197246 as the three most compelling cFSVs for breast cancer risk. The first two SVs are 435 bp apart in CASP8, while rs10197246 resides 81kb telomeric within the adjacent ALS2CR12 gene. Despite the 81 kb physical separation, all three cFSVs target CASP8, based on the eQTL data. While all 3 lie on the risk haplotype, LD between rs3769823/rs3769821 and rs10197246 is not particularly strong (r 2 =0.66) suggesting that there may be two functional hits on the haplotype. This hypothesis is consistent with the luciferase enhancer activity results that illustrates that risk alleles at both rs3769823/rs3769821 and rs10197246 independently and significantly decreased enhancer activity. Of particular interest was that CASP8 expression differences were consistently stronger in normal breast tissue compared to breast tumor material, both in the frozen tissue samples (RNAseq data) and the representative cell lines (enhancer assays). These observations support the hypothesis that these three variants are functionally relevant breast cancer risk variants that create an environment more conducive to tumorigenesis by reducing CASP8 gene expression (and hence levels of apoptosis) in the normal breast. Moving forward, MYC-triggered apoptosis may be one possible mechanism worthy of investigation, given rs3769823 and rs10197246 appear good functional candidates and both reside in regions bound by MYC in the breast cancer cell line MCF-7. The importance of CASP8 in breast cancer tumorigenesis was also recently underscored by its identification as one of 32 genes significantly somatically mutated in breast cancer tumors (24) , and one of only 22 genes identified as significantly mutated in at least 3 different common tumor types (25) , suggesting that other common cancers may follow the pattern for susceptibility that we see here.
Our interrogation of the 2q33 breast cancer risk locus implicates extremely common FSVs (RAF~0.28) with small effect sizes (~17% decreased gene expression), consistent with the common disease common variant model. The largely non-coding candidates identified and the consistent stronger significance in normal tissues suggest that greater availability of resources for gene-expression and other epigenetic data in normal tissues may prove critical in the prioritization and identification of common, low-risk variants. Initiatives such as the Roadmap Epigenomics Project and ENCODE will certainly help in this regard as they come to fruition (26) . Here, we were successful in illustrating differences in 88 local samples that could be replicated based on 97 samples from TCGA. However, in general, much larger sample sizes may be needed to generate robust findings.
Our small, focused, discordant haplotype DNAseq study identified 18 cFSVs for the CASP8/ALS2CR12 region. These results aligned with and extended the 16 cFSV suggested from a traditional fine-mapping association study almost four orders of magnitude larger, leading to a combined set of 25 cFSVs, and resulting in three variants (rs3769823, rs3769821, and rs10197246) implicated as functionally relevant breast cancer risk alleles influencing CASP8 expression. The discordant haplotype sequencing and traditional finemapping approaches have distinctly different strengths and weaknesses: statistically, technologically, and economically. Large population-based association studies attain good power to identify common, low-risk loci with accurate risk estimates, but fine-mapping efforts remain largely constrained to imputation because sequencing costs are prohibitive.
The discordant haplotype design attains excellent power specifically for the locus for which they are optimized, and is therefore cost effective for DNAseq, but needs to be carried out separately for each association signal if there is more than one in a region. A noteworthy limitation of both approaches is the challenge posed by repetitive DNA sequences, with around 50% of the human genome consisting of repetitive elements (27) . For targeted capture it is not possible to design uniquely-mapping capture baits for these regions, and for any HTS technology, alignment is difficult across repetitive elements. In our discordant haplotype study, for example, we were able to capture only 61% of the region at a read depth of ≥10× (average 76× depth across the full capture). In particular, we did not identify 7 SV that were available in the BCAC imputation study. Highly repetitive sequence impacts imputation studies differently. Repetitive regions are likely to harbor increased rates of misalignment, leading to non-random genotype errors in the reference panel from which imputations are made. Quality scores may not easily identify such errors. An example of this in the exome design is the appearance of highly variable 'promiscuous' genes within gene families with a high degree of identity at the nucleotide level. Additionally, the 1000G phase 3 data, frequently used as a whole genome imputation reference panel, have only a ~4-6× average read depth across the majority of the non-coding regions of the genome leading to low quality genotypes and an over-abundance of homozygotes. To investigate this phenomenon, we downloaded all Caucasian 1000G whole genome .bam files that were indicated to have passed quality control. We performed a best practice haplotypeCaller GATK variant calling pipeline on these 191 genomes, and inspected the data for the 7 SVs imputed in the BCAC study but not captured by baits in the current DNAseq study. As expected, the 1000G sequencing coverage for these 7 SVs was low (median DP = 5-7×).
Call rates ranged from 83-99%. Of those called, individual-level genotype qualities were relatively poor (median GQ=15-24; GQ<20 often considered unreliable, GQ≥30 often used as a quality filter). Hence both designs are affected by repetitive genome sequences, albeit in slightly different ways, adding further value to a joint-interpretation approach. We conclude that these two approaches are extremely complementary and suggest that DNAseq in a nested discordant haplotype design within larger case-control studies could play an important role in identifying comprehensive short-lists for functional studies.
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